-
Duality Biotherapeutics Clears HKEX Hearing, Set for IPO with $2.7B Valuation
•
Duality Biotherapeutics, Inc., a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs), has successfully passed the Hong Kong Stock Exchange (HKEX) listing hearing and disclosed its post-hearing information on March 23. Morgan Stanley, Jefferies, and CITIC Securities Company Limited are serving as joint sponsors for the IPO. Pipeline and…
-
Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services
•
Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline offerings, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. This move marks a significant step in the company’s growth strategy and capital market expansion. Company OverviewSince its inception in…
-
PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services
•
Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed for an initial public offering (IPO) with the US Securities and Exchange Commission (SEC). The company aims to list on the Nasdaq under the ticker symbol POM, marking a significant step in its growth strategy.…
-
Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies
•
China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully launched its initial public offering (IPO) on the Hong Kong Stock Exchange. The offering price ranges from HKD68.44 to HKD75.28 per share, with net proceeds potentially reaching HKD603.3 million (USD77.6 million) if calculated at the…
-
Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules
•
China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE) late last week, taking advantage of the Chapter 18A rules to list as a pre-profit biotech company. Morgan Stanley, Jefferies Financial, and CITIC Securities act as its co-sponsors. Company Overview and PipelineSince…
-
Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio
•
Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing in the Hong Kong Stock Exchange, with the unit price and other details not yet disclosed. Product PortfolioHuge Dental boasts a diverse product portfolio covering oral clinical products, dental technician products, and oral digital products.…
-
Biointron Biologics Files for Public Offering, Aims for BSE Listing
•
On February 11, Biointron Biologics released its tutoring filing report for the public offering of shares to unspecified qualified investors and listing on the Beijing Stock Exchange (BSE). The tutoring work is led by Haitong Securities Co., Ltd., with Grandway Law Offices and Grant Thornton China (Special General Partnership) responsible…
-
Genuine Biotech Files for Hong Kong IPO with Azvudine and ZS-1003 in Pipeline
•
China-based Genuine Biotech Limited has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, according to the bourse’s website. Key details such as the unit price and offering size have not yet been disclosed. Company ProfileGenuine Biotech is focused on the development, manufacturing, and commercialization of…
-
Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor
•
China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan to subscribe to shares of Visen Pharmaceuticals via its initial public offering (IPO) on the Hong Kong Stock Exchange. Anhui Anke will invest up to USD31 million as a cornerstone investor. About Visen PharmaceuticalsVisen Pharmaceuticals…
-
Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange
•
Suzhou-based Vigonvita Life Sciences Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking a listing on the bourse. This move marks a significant step for the company as it looks to expand its market presence and raise capital for future growth. Company…
-
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
•
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co., Ltd., a Suzhou-based specialist in endocrine metabolism, has successfully passed the HKEX hearing. China International Capital Corporation (CICC) acted as the sole sponsor. Company OverviewPegBio was established in 2008 as a biotechnology company focused on…
-
Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model
•
On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor. Company Overview and MissionThe prospectus shows that Vigonvita Bio, established in 2013, is an integrated biopharmaceutical company…
-
Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits
•
Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing notice from the China Securities Regulatory Commission (CSRC) regarding its initial public offering (IPO) of 46,620,000 shares in Hong Kong. The company filed its prospectus with the Hong Kong Stock Exchange in November of last…
-
Ascentage Pharma Prices US IPO at USD 17.25 per ADS
•
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market…
-
Shanghai Bao Pharmaceuticals Launches IPO to Advance Biopharmaceutical Pipeline
•
China-based Shanghai Bao Pharmaceuticals Co., Ltd., a high-end biopharmaceuticals developer, has announced its initial public offering (IPO). Specific details regarding the unit price and other IPO particulars have not been disclosed at this stage. Company Background and PipelineSince its inception in 2019, Bao Pharma has focused on improving treatment standards…
-
Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application for an initial public offering (IPO) to the Hong Kong Stock Exchange. The company also published the application documents on the exchange’s website on the same day. This move follows the expiration of its previous…
-
Fujian Haixi Pharmaceuticals Files for Hong Kong IPO
•
China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE). The company has not disclosed the unit price or other key details at this stage, but the move marks a significant step in its…
-
Sepax Technologies Debuts on STAR Market with Soaring IPO Prices
•
Sino-US firm Sepax Technologies Co., Inc. has successfully completed its initial public offering (IPO) on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The opening price of RMB 28.15 per share marked a significant increase of 551% from the issue price of RMB 4.32. The final closing price settled at…
-
TCMTech Files for IPO on Hong Kong Stock Exchange, Showcasing TCM AI Leadership
•
China-based TCMTech Inc., recognized as the largest artificial intelligence (AI) empowered traditional Chinese medicine (TCM) medical service provider in its homeland in 2023, has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. This move marks a significant step in the company’s growth and expansion strategy.…
-
BrainAurora Medical Technology IPOs on Hong Kong Stock Exchange
•
Zhejiang-based BrainAurora Medical Technology Limited (HKG: 6681), the first company in China to combine neuroscience and artificial intelligence (AI) technology for developing medical-grade digital therapy products, has successfully completed an initial public offering (IPO) of 181,112,000 shares on the Hong Kong Stock Exchange. The offering, priced at HKD 3.22 per…
